NFKB1 and neoplasm: Bortezomib inhibits tumor proliferation in various types of cancers, including gastric, breast, ovarian, and pancreatic tumors; additionally, the drug blocks the activity of NF-κB1 and reduces resistance to doxorubicin, making it a potential drug for treating patients with anthracycline-containing regimens resistant tumors [129].